Navigation Links
ISTA Pharmaceuticals Announces Conference Call and Webcast of Fourth Quarter 2007 Financial Results
Date:3/4/2008

IRVINE, Calif., March 4 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA), today announced it will release fourth quarter 2007 financial results on March 6, 2008, after the U.S. markets close. ISTA will host a conference call, with a simultaneous webcast, to discuss these results and provide a commercial and pipeline update at 5:00 p.m. Eastern Time on March 6.

To access the live conference call, U.S. and Canadian participants may dial 866-831-6270; international participants may dial 617-213-8858. The access code for the live call is 99457780. To access the 24-hour audio replay, U.S. and Canadian participants may dial 888-286-8010; international participants may dial 617-801-6888. The access code for the replay is 57762235. This conference call also will be webcast live and archived on ISTA's website until April 7, 2008, at http://www.istavision.com.

About ISTA

ISTA Pharmaceuticals is an ophthalmic pharmaceutical company. ISTA's products and product candidates addressing the $4.7 billion U.S. prescription ophthalmic industry include therapies for inflammation, ocular pain, glaucoma, allergy, and dry eye. The Company currently markets three products and is developing a strong product pipeline to fuel future growth and market share. The Company's product development and commercialization strategy is to launch a new product every 12 to 18 months, thereby continuing its growth to become the leading niche ophthalmic pharmaceutical company in the U.S. For additional information regarding ISTA, please visit ISTA Pharmaceuticals' website at http://www.istavision.com.


'/>"/>
SOURCE ISTA Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Affinium Pharmaceuticals, Ltd. Announces Initiation of a Phase I Clinical Trial for AFN-1252, its Novel Anti-staphylococcal Antibiotic
2. Indevus Pharmaceuticals Announces Retirement Plans For Its CEO and Chairman
3. MAP Pharmaceuticals Reports 2007 Fourth Quarter and Year End Financial Results
4. Acura Pharmaceuticals, Inc. Announces Andrew Reddick, President & CEO, To Take Medical Leave and Appointment of Richard Markham as Chairman of the Board
5. Idenix Pharmaceuticals to Present at the SIGnificant Investment Options in Healthcare Conference
6. VIA Pharmaceuticals to Present at Susquehanna and Rodman & Renshaw Conferences on March 4, 2008
7. Lotus Pharmaceuticals Raises $5 Million in Private Placement
8. Galderma Reaches Agreement to Acquire CollaGenex Pharmaceuticals
9. Transcept Pharmaceuticals to Present at the Susquehanna Financial Groups SIGnificant Investment Options in Healthcare Conference
10. Onyx Pharmaceuticals Reports Fourth Quarter and Twelve-Month 2007 Financial Results
11. RHEI Pharmaceuticals Licenses Attental From MethaPharma (Vemedia Group) for Distribution Throughout Asia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... 2017 , ... It's not always common knowledge whether or not a certain ... as to whether or not they are contagious, and most people don't know the ... FindaTopDoc took a look into the matter. , They discovered that the main ...
(Date:4/28/2017)... ... 2017 , ... Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ) announced ... its outlook as “stable.” At the same time, the ratings agency cautioned that the ... dip below “capital adequacy” thresholds required for its strong rating. , “Horizon is committed ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... http://www.wiredlifesolutions.com , “Computers are everywhere and they’re here to stay,” said ... Global Climate Change and Your Health on Voice America sponsored by Nature’s Tears® ...
(Date:4/28/2017)... york (PRWEB) , ... April 28, 2017 , ... ... to announce that Aditya Patel M.D. has joined the revolutionary endoscopic practice under ... and board certification in Interventional Pain Medicine. The patented, revolutionary eDiscSculpt Technique created ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... and College of Urgent Care Medicine will host industry leaders for the annual ... will help those in the industry adapt to the issues currently affecting urgent ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... Research and Markets has announced ... Market Prospects: Addressing Production Complexities Through Risk Management and ... ... Pipeline and Market Prospects: Overcoming Production Complexities Through Risk ... of the current trends in the global biosimilars market, ...
(Date:4/20/2017)... , April 20, 2017   ZappRx, Inc ., ... specialty drug prescribing process, today announced it closed $25 million ... a venture capital firm based in Seattle ... Qiming Venture Partners . The Series B round included participation ... round in 2014, and GV (formerly Google Ventures). ...
(Date:4/20/2017)... NeuroVive Pharmaceutical AB (Nasdaq Stockholm: ... preclinical results demonstrating anti-fibrotic effects with NV556, ... (NASH), in an additional well-validated experimental NASH ... previously shown similar anti-fibrotic effects in the ... present novel data demonstrating anti-fibrotic effects of ...
Breaking Medicine Technology: